Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06689254 | REVERSE: Improving Treatment-resistant Post Traumatic Stress Disorder (PTSD) with Glucocorticoid Receptor (GR) Antagonism | PHASE2 | RECRUITING | 60 | — | — | Nov 15, 2024 | Nov 15, 2026 | Nov 14, 2024 | 1 | Netherlands |
Measured with the monthly version of the CAPS-5 (Clinician Administered PTSD scale) in patients with treatment-resistant PTSD. Minimum and maximum score range from 0-80, with higher scores indicating greater PTSD symptom severity.
| Arm | Type | Description |
|---|---|---|
| Mifepristone | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Mifepristone 1200 mg daily | DRUG | Oral tablets |
| Placebo | DRUG | Oral tablet |
Inclusion Criteria: * Mastery of Dutch language * Age of ≥ 18 years of age and able to give written IC * Participant agrees to be randomized * DSM-5 diagnosis of PTSD, confirmed with clinical interview (CAPS-5) * Treatment-resistant PTSD * CAPS-5 score ≥ 30 * Nonresponse to two evidence-based ...